[ABBV] Considering the difficult regulatory environment facing developers working within the HCV nucleotide analog class the FDA could be looking to the ABBV combo as a SOC proxy towards future GT1 development. The GILD combo clearly will become the next SOC in GT2.
Market Data 
Markets 
AI
